SWOG S1400F: A Phase II Study of MEDI4736 (DURVALUMB) Plus TREMELIMUMAB as Therapy for Patients with Previously Treated ANTI-PD-/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer


This phase II trial studies how well durvalumab and tremelimumab works in treating patients with stage IV lung cancer that has come back after previous treatment. Monoclonal antibodies, such as durvalumab and tremelimumab, may interfere with the ability of tumor cells to grow and spread.

More information

Contact us

To learn more about clinical trials at ProHealth Care, email research.institute@phci.org or call 262-928-3447.

Quick Access Links